Levosimendan Administration in Pulmonary Hypertension

• Status: Recruiting
• Trial end date: 2022-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to examine the pharmacokinetics and pharmacodynamic properties of Levosimendan in cardiac surgery patients with pulmonary hypertension and impaired right ventricular function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aretaieion University Hospital
• Treatments: Simendan

Criteria

Inclusion Criteria:

• patients with pulmonary hypertension due to left ventricular dysfunction based on echocardiographic diagnosis preoperatively

• elective cardiac surgery

Exclusion Criteria:

• primary pulmonary hypertension

• thromboembolic disease

• chronic obstructive pulmonary disease

• emergency surgery

• redo surgery

• inability to consent to the study